This standard operating protocol outlines treatment and diagnosis for malaria, emphasizing WHO recommendations and timely intervention.
Despite a decline in malaria-related deaths over the past two decades, the global malaria burden remains high, particularly in endemic low- and middle-income countries. This standard operating protocol outlines a simplified, evidence-based approach to rapid clinical decision-making for malaria, primarily based on WHO recommendations. Early diagnosis and severity assessment are essential for timely and appropriate treatment. All suspected cases should undergo parasitological confirmation with a peripheral smear or rapid diagnostic test before treatment initiation (except in suspected severe cases where testing is not immediately feasible). Artemisinin-based treatment remains the mainstay: oral artemisinin-based combination therapy for uncomplicated malaria and intravenous artesunate for severe cases, including pregnant women (all trimesters) and children. Glucose-6-phosphate dehydrogenase testing is not required for single-dose gametocytocidal primaquine, but is essential prior to radical cure with primaquine or tafenoquine.
No takes yet. Share an insight, caveat, or question.
Ashok Kumar Pannu (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: